NewAmsterdam Pharma Company N.V.
NAMS
$36.47
-$3.98-9.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.01M | 47.14M | 45.56M | 33.59M | 7.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.01M | 47.14M | 45.56M | 33.59M | 7.42M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 64.01M | 47.14M | 45.56M | 33.59M | 7.42M |
| SG&A Expenses | 93.93M | 83.15M | 70.45M | 59.93M | 50.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 236.80M | 236.87M | 221.85M | 217.73M | 216.11M |
| Operating Income | -172.79M | -189.73M | -176.29M | -184.13M | -208.69M |
| Income Before Tax | -165.72M | -187.36M | -241.60M | -198.89M | -229.38M |
| Income Tax Expenses | -1.00K | -1.00K | -1.00K | 26.00K | 27.00K |
| Earnings from Continuing Operations | -165.72 | -187.36 | -241.60 | -198.92 | -229.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.72M | -187.36M | -241.60M | -198.92M | -229.40M |
| EBIT | -172.79M | -189.73M | -176.29M | -184.13M | -208.69M |
| EBITDA | -172.62M | -189.58M | -176.18M | -184.06M | -208.63M |
| EPS Basic | -1.59 | -1.86 | -2.58 | -2.25 | -2.64 |
| Normalized Basic EPS | -0.97 | -1.15 | -1.52 | -1.39 | -1.66 |
| EPS Diluted | -1.59 | -1.86 | -2.58 | -2.25 | -2.64 |
| Normalized Diluted EPS | -0.97 | -1.15 | -1.52 | -1.39 | -1.66 |
| Average Basic Shares Outstanding | 428.87M | 405.02M | 377.28M | 360.32M | 348.03M |
| Average Diluted Shares Outstanding | 428.87M | 405.02M | 377.28M | 360.32M | 348.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |